Clinical trials: Renal Allograft
Kidney Transplantation Recipients, Sodium-Glucose Transporter 2 Inhibitors
SGLT2i Safety and Efficacy on Kidney Allograft Function in Non-diabetic Kidney Transplant Recipients
This clinical trial investigates whether 18 months of daily SGLT2i (10 mg Forxiga) preserves kidney function and evaluates safety, based on eGFR changes and adverse event occurrence in non-diabetic kidney transplant recipients.
- Conditions
- Kidney Transplantation Recipients, Sodium-Glucose Transporter 2 Inhibitors, Non-Diabetic Patients, Randomized Controlled Trial
- Trial name
- SGL-TX-GFR (NCT07143773)
- Testing
- SGLT-2 inhibitor
- Where
- Denmark
- Volunteers
- 88 people
- Sponsor
- Odense University Hospital
Kidney Transplant Rejection
Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation
This study will evaluate the safety and efficacy of AT-1501 compared with tacrolimus in patients undergoing kidney transplantation.
- Trial name
- NCT05983770
- Testing
- AT-1501, Tacrolimus
- Where
- 43 sites in United States, Australia and 5 more
- Volunteers
- 127 people
- Sponsor
- Eledon Pharmaceuticals
Kidney Transplant, Liver Transplant
A Cohort Study of Operationally Tolerant Allograft Recipients
Antirejection medicines, also known as immunosuppressive drugs, are prescribed to organ transplant recipients to prevent their bodies from rejecting the new organ.
- Trial name
- ALLTOL (NCT02743793)
- Testing
- Blood Draw
- Where
- 5 sites in United States
- Volunteers
- 41 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Kidney Transplantation
Performances of Large Language Models in Kidney Allograft Diagnostics
Kidney allograft rejection diagnosis relies on the complex Banff classification, but its application is limited by variability and workload.
- Trial name
- NCT07004660
- Volunteers
- 240 people
- Sponsor
- Paris Translational Research Center for Organ Transplantation
Renal Transplantation
Efficacy and Safety of Everolimus in Combination With Cyclosporine Microemulsion Versus Everolimus in Combination With Enteric-coated Mycophenolate Sodium (EC-MPS), in Adult Renal Transplant Patients in Maintenance.
Efficacy and safety of 2 groups of treatment: everolimus in association with cyclosporine microemulsion and steroids versus everolimus in association with Enteric-coated Mycophenolate Sodium (EC-MPS) and steroids.
- Trial name
- NCT00425308
- Testing
- Everolimus + Cyclosporine, Everolimus + Enteric-coated Mycophenolate Sodium (EC-MPS), Steroids
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Novartis Pharmaceuticals
Kidney Transplantation
Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients
This study was to compare CFZ533 to tacrolimus (TAC) in prevention of organ rejection in kidney transplant.
- Trial name
- CIRRUS I (NCT03663335)
- Testing
- CFZ533 - Cohort 1/Cohort 2, Mycophenolate Mofetil (MMF), Corticosteroids (CS)
- Where
- 74 sites in United States, Argentina and 18 more
- Volunteers
- 418 people
- Sponsor
- Novartis Pharmaceuticals
Ischemia-reperfusion Injury, Kidney Transplant; Complications
A Trial to Assess Efficacy and Safety of ex Vivo Allograft Admin of iCM012 Solution 2 mg/ml to Improve Its Function in Recipients of DCD Kidneys
Randomized (1:1), placebo controlled, double blind efficacy trial. 200 patients will be followed up for 12 months post transplantation.
- Trial name
- NCT06582485
- Testing
- iCM012 solution 2 mg/mL
- Volunteers
- 200 people
- Sponsor
- iCoat Medical AB
Medication Adherence, Kidney Transplantation
Teen Adherence in KidnEy Transplant Improving Tracking To Optimize Outcomes - Stage 3
Medication non-adherence is a major problem in kidney transplant recipients; young people 12-24 years of age are at particularly high risk for non-adherence and graft failure compared to young children and adults.
- Trial name
- NCT04288271
- Testing
- Adherence Intervention, Healthy living education intervention
- Where
- 8 sites in United States, Canada
- Volunteers
- 96 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Kidney Transplant
Mycophenolate Mofetil and Rapamycin as Secondary Intervention vs. Continuation of Calcineurin Inhibitors in Patients at Risk for Chronic Renal Allograft Failure
A study to determine the effect on renal function in renal transplant patients with biopsy proven Chronic allograft nephropathy (CAN) nephropathy who are switched from a Calcinerin inhibitor (CI) triple drug regimen to a…
- Trial name
- NCT00223678
- Testing
- Rapamycin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Vanderbilt University Medical Center
Kidney Transplantation, Plasmapheresis
Study to Evaluate the Amount of Medications That May be Removed From the Body During Plasmapheresis
Based on the limited amount of experience with plasmapheresis and CytoGam concomitant use, the researchers seek to evaluate the pharmacokinetics (drug absorption, distribution, and elimination) of this therapy.
- Trial name
- NCT00203281
- Testing
- tacrolimus, mycophenolate mofetil, daclizumab
- Where
- 2 sites in United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Kidney Disease
Angiotensin-Converting Enzyme Gene Polymorphism and the Risk of Chronic Allograft Nephropathy
This study is intended to help doctors learn about the relationships between specific genetic makeup (gene markers) and the development of chronic rejection.
- Trial name
- NCT00006328
- Where
- United States
- Sponsor
- National Center for Research Resources (NCRR)
Kidney Transplantation, Chronic Allograft Nephropathy
Antibody and Delayed Cyclosporine Versus Initial Cyclosporine Alone in Patients Receiving Kidney Transplants
The purpose of this study is to see if kidney function can be improved during transplants by giving the drug Thymoglobulin with delayed cyclosporine treatment instead of initial cyclosporine treatment.
- Trial name
- NCT00007787
- Testing
- Cyclosporine, Anti-human thymocyte globulin (rabbit), Tacrolimus
- Where
- United States
- Volunteers
- 350 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Graft Rejection, Kidney Transplantation
TRAnscriptional Profile of Peripheral Blood Cells in Patient With Chronic Kidney and Lung Rejection: Correlation With Response to Extracorporeal Photo-aphereSiS
With this project, the research team aims to identify the molecular pathways associated with the response to extracorporeal photonchemioapheresis (ECP) in kidney or lung transplant patients suffering from chronic rejection, by…
- Conditions
- Graft Rejection, Kidney Transplantation, Lung Transplantation, Antibody-Mediated Rejection
- Trial name
- TRACKLESS (NCT07316829)
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Kidney Rejection Transplant
Molecular Transcriptomics in Diagnosing Pediatric Kidney Transplant Rejection: the PANDA-Kids-ATLAS Study
Children with kidney failure have markedly increased mortality and face repeated transplantation over their lifetime due to limited allograft half-life (12-15 years).
- Trial name
- NCT07091214
- Where
- France
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Paris Translational Research Center for Organ Transplantation
End-Stage Renal Disease, Kidney Transplantation
A Study to Compare Treatment With Sirolimus Versus Standard Treatment in Patients Who Have Received a Kidney Transplant
The purpose of this study is to compare treatment with the new drug sirolimus (SRL) versus the standard treatment with cyclosporine (CsA) or tacrolimus in children who have received kidney transplants.
- Trial name
- NCT00005113
- Testing
- Cyclosporine, Sirolimus, Tacrolimus
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- Boston Children's Hospital
Kidney Transplantation
A 6-Month Study Of CP-690,550 Versus Tacrolimus In Kidney Transplant Patients
This Phase 2 study was designed to evaluate the safety and efficacy of 2 dose levels of CP-690,550 (15 mg twice daily and 30 mg twice) against tacrolimus, in combination with basiliximab induction, mycophenolate mofetil and…
- Trial name
- NCT00106639
- Testing
- CP-690,550, tacrolimus
- Where
- 20 sites in United States
- Volunteers
- 61 people
- Sponsor
- Pfizer
Antibody Mediated Rejection
A Two Part Dose-escalation Safety and Efficacy Study of CID-103 in Adults With Active and Chronic Active Renal Allograft Antibody Mediated Rejection (ABMR).
The goal of the global Phase 1/2 clinical trial is to evaluate whether CID-103, a novel anti-CD38 monoclonal antibody, is safe and effective in adults with with active and chronic active renal allograft antibody mediated…
- Trial name
- NCT07641426
- Testing
- CID-103
- Where
- 4 sites in China
- Volunteers
- 58 people
- Sponsor
- CASI pharmaceuticals, Inc.
Renal Cell Carcinoma
Transplantation of Reconstructed Renal Allografts Following Ex-Vivo Partial Nephrectomy
This study is designed to investigate a novel approach to offer more ESRD participants the benefits associated with renal transplantation by increasing the supply of available allografts
- Trial name
- NCT05725421
- Testing
- Donor Radical and Partial Nephrectomy, Kidney Transplantation, Laparoscopic Radical Nephrectomy
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Case Comprehensive Cancer Center
Kidney Transplantation, Kidney Disease
Prediction of Chronic Allograft Nephropathy
The investigators have shown that epithelial-to-mesenchymal transition (EMT) markers in early protocol biopsies of the renal allograft predicts the progression of fibrosis during the first year post-transplantation.
- Conditions
- Kidney Transplantation, Kidney Disease, Kidney Failure, Chronic
- Trial name
- Prefigur (NCT01380847)
- Testing
- mRNAs encoding genes
- Where
- France
- Volunteers
- 300 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Delayed Graft Function, End Stage Renal Disease
Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation
A Phase 3 Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation
- Conditions
- Delayed Graft Function, End Stage Renal Disease, Deceased Donor Kidney Transplant
- Trial name
- NCT07020832
- Testing
- Pegcetacoplan
- Where
- Brazil
- Sponsor
- Apellis Pharmaceuticals, Inc.